Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study.
Cisplatin-based drug combinations are now currently investigated in an attempt to surpass the results obtainable by 5-FU alone or by 5-FU-containing regimens. We evaluated 29 patients with advanced and measurable gastric adenocarcinoma treated with etoposide, epirubicin and cisplatin. One patient had complete response (3 +/- 7%); 9 patients had partial response (31 +/- 17%); 5 patients (17 +/- 14%) were considered stable (S) and 14 (48 +/- 18%) were classified as progressive. The average survival time for the entire group was 11 months with 25% of the patients alive at 24 months. We feel that cisplatin-containing regimens are promising and deserve further investigations. To clearly explore the potential innovative role of these regimens randomized trials versus FAM or 5-FU alone are mandatory.
Barone
C
C
Istituto di Clinica Medica, Università Cattolica S. Cuore, Roma, Italia.
Cassano
A
A
Astone
A
A
Ricevuto
E
E
Fontana
T
T
Noviello
M R
MR
Garufi
C
C
Pacelli
F
F
Grieco
A
A
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage*; D015251:Epirubicin / Q000008:administration & dosage*; D005047:Etoposide / Q000008:administration & dosage*; D006801:Humans; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy*
D015251:Epirubicin; D005047:Etoposide; D002945:Cisplatin